Clinical epigenetics: seizing opportunities for translation
M Berdasco, M Esteller - Nature Reviews Genetics, 2019 - nature.com
Biomarker discovery and validation are necessary for improving the prediction of clinical
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …
outcomes and patient monitoring. Despite considerable interest in biomarker discovery and …
HIV-associated neurocognitive disorder
DB Clifford, BM Ances - The Lancet infectious diseases, 2013 - thelancet.com
Neurological involvement in HIV is often associated with cognitive impairment. Although
severe and progressive neurocognitive impairment has become rare in HIV clinics in the era …
severe and progressive neurocognitive impairment has become rare in HIV clinics in the era …
[HTML][HTML] HIV reservoirs as obstacles and opportunities for an HIV cure
The persistence of HIV reservoirs remains a formidable obstacle to achieving sustained
virologic remission in HIV-infected individuals after antiretroviral therapy (ART) is …
virologic remission in HIV-infected individuals after antiretroviral therapy (ART) is …
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs
C Katlama, SG Deeks, B Autran, J Martinez-Picado… - The Lancet, 2013 - thelancet.com
Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to
regimens that are both expensive and associated with toxic effects. A curative intervention …
regimens that are both expensive and associated with toxic effects. A curative intervention …
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
Latent HIV reservoirs are the primary hurdle to eradication of infection. Identification of
agents, pathways and molecular mechanisms that activate latent provirus may, in the …
agents, pathways and molecular mechanisms that activate latent provirus may, in the …
[HTML][HTML] Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir
M Pardons, B Cole, L Lambrechts… - Nature …, 2023 - nature.com
The development of latency reversing agents that potently reactivate HIV without inducing
global T cell activation would benefit the field of HIV reservoir research and could pave the …
global T cell activation would benefit the field of HIV reservoir research and could pave the …
[HTML][HTML] Multiple origins of virus persistence during natural control of HIV infection
EA Boritz, S Darko, L Swaszek, G Wolf, D Wells, X Wu… - Cell, 2016 - cell.com
Targeted HIV cure strategies require definition of the mechanisms that maintain the virus.
Here, we tracked HIV replication and the persistence of infected CD4 T cells in individuals …
Here, we tracked HIV replication and the persistence of infected CD4 T cells in individuals …
[HTML][HTML] HIV-1 transcription and latency: an update
C Van Lint, S Bouchat, A Marcello - Retrovirology, 2013 - Springer
Combination antiretroviral therapy, despite being potent and life-prolonging, is not curative
and does not eradicate HIV-1 infection since interruption of treatment inevitably results in a …
and does not eradicate HIV-1 infection since interruption of treatment inevitably results in a …
Reactivation of latent HIV by histone deacetylase inhibitors
K Shirakawa, L Chavez, S Hakre, V Calvanese… - Trends in …, 2013 - cell.com
Latent HIV persists in CD4+ T cells in infected patients under antiretroviral therapy (ART).
Latency is associated with transcriptional silencing of the integrated provirus and driven, at …
Latency is associated with transcriptional silencing of the integrated provirus and driven, at …
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation
TA Rasmussen, OS Søgaard, C Brinkmann… - Human vaccines & …, 2013 - Taylor & Francis
Objective: We aimed to compare the potential for inducing HIV production and the effect on T-
cell activation of potent HDAC inhibitors undergoing clinical investigation. Design: In vitro …
cell activation of potent HDAC inhibitors undergoing clinical investigation. Design: In vitro …